SG11201810765PA - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same - Google Patents
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using sameInfo
- Publication number
- SG11201810765PA SG11201810765PA SG11201810765PA SG11201810765PA SG11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA
- Authority
- SG
- Singapore
- Prior art keywords
- fatty acid
- bhb
- california
- international
- acid esters
- Prior art date
Links
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 title abstract 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000002711 medium chain fatty acid esters Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 5
- 229930195729 fatty acid Natural products 0.000 abstract 5
- 239000000194 fatty acid Substances 0.000 abstract 5
- -1 fatty acid esters Chemical class 0.000 abstract 3
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 abstract 1
- 241001263180 Auriparus flaviceps Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Abstract
CBHB Q.41 millimoles 04. C6-BHB 0.21 C8-BHB 0.35 rniiiirnoles C8-BHB 0.18 millimales BHB 025 miltimoles 4- Fasting (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT 0111111010 0111 inn Holm nacnum (10) International Publication Number WO 2017/213999 Al (51) International Patent Classification: G02F 1/1368 (2006.01) G02F 1/13363 (2006.01) G02B 1/08 (2006.01) G02F 1/1335 (2006.01) G02B 5/30 (2006.01) (21) International Application Number: PCT/US2017/035826 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/346,975 07 June 2016 (07.06.2016) US (71) Applicants: THE J. DAVID GLADSTONE INSTI- TUTES [US/US]; 1650 Owens Street, San Francis- co, California 94158 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, California 94607 (US). ITHACA COLLEGE [US/US]; 953 Danby Road, Ithaca, New York 14850 (US). (72) Inventors: VERDIN, Eric; 141 Tamalpais Avenue, Mill Valley, California 94941 (US). ULRICH, Scott; 649 Val- ley Rd., Brooktondate, New York 14817 (US). NEWMAN, John; 545 Burnett Ave., Apt 102, San Francisco, California 94131 (US). (74) Agent: RUBIN, Michael B.; Bozicevic, Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (54) Title: MEDIUM CHAIN FATTY ACID ESTERS OF BETA-HYDROXYBUTYRATE AND BUTANEDIOL AND COM- POSITIONS AND METHODS FOR USING SAME BHB vs BHB-esters alter injection Figure 6c (57) : Aspects of the present disclosure include fatty acid [3-hydroxyester compounds (e.g., fatty acid esters of (3-hydroxybu- tyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid [3-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described. [Continued on next page] WO 2017/213999 Al MIDEDIMOMOIMIRMEM0011010CMCHIMINHOIS SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346975P | 2016-06-07 | 2016-06-07 | |
PCT/US2017/035826 WO2017213999A1 (en) | 2016-06-07 | 2017-06-02 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810765PA true SG11201810765PA (en) | 2018-12-28 |
Family
ID=60578899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810765PA SG11201810765PA (en) | 2016-06-07 | 2017-06-02 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
Country Status (13)
Country | Link |
---|---|
US (4) | US10889538B2 (en) |
EP (1) | EP3465335A4 (en) |
JP (3) | JP7058610B2 (en) |
KR (2) | KR102519244B1 (en) |
CN (2) | CN109477993B (en) |
AU (2) | AU2017278099B2 (en) |
CA (1) | CA3026621A1 (en) |
CO (1) | CO2018014167A2 (en) |
IL (2) | IL263561B (en) |
MX (2) | MX2021009806A (en) |
RU (1) | RU2761829C2 (en) |
SG (1) | SG11201810765PA (en) |
WO (1) | WO2017213999A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2761829C2 (en) | 2016-06-07 | 2021-12-13 | Зе Дж. Дэвид Глэдстоун Инститьютс | Esters of beta-hydroxybutyrate and butanediol formed by medium-chain fatty acids and compositions and methods based on them |
BR112020001285A2 (en) | 2017-07-21 | 2020-07-28 | Buck Institute For Research On Aging | beta-hydroxybutyrate and butanediol s-enantiomers and methods for their use |
WO2019161047A1 (en) * | 2018-02-14 | 2019-08-22 | Bickman Benjamin | Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health |
US11919851B2 (en) * | 2019-01-17 | 2024-03-05 | Ketolipix Therapeutics Gmbh | Method for producing polyol-based esters of optionally acylated hydroxycarboxylic acids |
BR112021014015A2 (en) * | 2019-01-17 | 2021-09-21 | Ioi Oleo Gmbh | METHOD FOR THE PRODUCTION OF FATTY ALCOHOL ESTERS OF HYDROXYCARBOXYLIC ACIDS |
JP7361124B2 (en) * | 2019-01-17 | 2023-10-13 | ケトリピックス セラポーティクス ゲーエムベーハー | Method for producing capped 3-hydroxycarboxylic acids and their salts and esters |
CN110372502A (en) * | 2019-07-25 | 2019-10-25 | 润泰化学(泰兴)有限公司 | A kind of double esterification synthetic method of 1,3- glycol |
GB201918657D0 (en) | 2019-12-17 | 2020-01-29 | Tdeltas Ltd | Compounds for new use |
CN116917264A (en) * | 2020-07-13 | 2023-10-20 | 凯托利皮克斯治疗有限责任公司 | Process for preparing hydroxybutyric acid carboxylic ester |
CN112341542B (en) * | 2021-01-08 | 2021-05-14 | 清华大学 | 3-hydroxybutyrylated modified protein medicine and preparation method and application thereof |
MX2023008675A (en) * | 2021-01-26 | 2023-08-02 | Buck Inst Res Aging | Use of exogenous ketone esters to induce weight loss in mammals. |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4263216A (en) * | 1978-10-20 | 1981-04-21 | The Procter & Gamble Company | Diglyceride manufacture |
IL59407A (en) * | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
US4436726A (en) | 1980-12-15 | 1984-03-13 | Fujisawa Pharmaceutical Co., Ltd. | N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions |
BE1001209A3 (en) | 1987-11-19 | 1989-08-22 | Solvay | PHARMACEUTICAL CONTAINING ACID DERIVATIVE 3-hydroxybutanoic CHOSEN AMONG OLIGOMERS OF THIS ACID AND ESTERS OF THIS ACID OR WITH THESE OLIGOMERS 1.3-BUTANEDIOL. |
US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
DE68923805T2 (en) | 1988-04-27 | 1995-12-07 | Daicel Chem | METHOD FOR PRODUCING OPTICALLY ACTIVE 1,3-BUTANEDIOL. |
JP2578658B2 (en) * | 1989-02-21 | 1997-02-05 | チッソ株式会社 | Optically active compound and method for producing the same |
US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
IT1240760B (en) * | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | ACYL-L-CARNITINE ESTERS WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA. |
DE69205560T2 (en) | 1992-01-08 | 1996-04-11 | Nestle Sa | Cosmetic and dermatological composition containing diol diesters. |
DE19703471A1 (en) * | 1997-01-31 | 1998-08-06 | Beiersdorf Ag | Cosmetic and dermatological sunscreen formulations containing triazine derivatives and butylene glycol diesters |
KR100839689B1 (en) | 1997-03-17 | 2008-06-18 | 비티지 인터내셔널 리미티드 | Therapeutic compositions |
JP4656675B2 (en) * | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | High rate encapsulation of charged therapeutic agents in lipid vesicles |
DE60001686T2 (en) * | 1999-05-11 | 2003-08-21 | Dow Agrosciences Llc | Process for the preparation of substituted 3-hydroxybutyric acid esters |
US20080009467A1 (en) | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
EP1363879A2 (en) * | 2000-10-11 | 2003-11-26 | Esperion Therapeutics Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
EP1528053A1 (en) | 2003-10-31 | 2005-05-04 | Lonza Ag | Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates |
JP2006063001A (en) | 2004-08-25 | 2006-03-09 | Takasago Internatl Corp | METHOD FOR PRODUCING OPTICALLY ACTIVE beta-BUTYROLACTONE |
US20070200087A1 (en) | 2006-02-10 | 2007-08-30 | Ann Wehner | Deicing and anti-icing compositions comprising renewably-based, biodegradable 1,3-propanediol |
JP5054418B2 (en) | 2007-04-23 | 2012-10-24 | ポーラ化成工業株式会社 | Skin external preparation suitable for cosmetics for cleansing |
AU2009283171B2 (en) | 2008-08-21 | 2014-08-14 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Hydroxybutyrate ester and medical use thereof |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
EP2419519B1 (en) | 2009-04-16 | 2019-03-27 | Oxford University Innovation Limited | Process for producing (3r)-hydroxybutyl (3r)-hydroxybutyrate by enzymatic enantioselective reduction employing alcohol dehydrogenases or keto reductases |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
CN107090090B (en) * | 2010-04-28 | 2022-05-17 | 阿科玛股份有限公司 | Method for improving the stability of polyurethane polyol blends containing halogenated olefin blowing agents |
KR101243240B1 (en) * | 2010-07-19 | 2013-04-04 | (주)에이씨티 | Novel derivatives of alkyldiol compound and whitening composition for external skin comprising the same |
CN103360243B (en) | 2012-03-31 | 2015-06-17 | 中国石油化工股份有限公司 | Preparation method of 1,3-diacyloxy dimethylmethane compound |
US20150085217A1 (en) * | 2012-05-01 | 2015-03-26 | Konica Minolta, Inc. | Retardation film, process for producing polarizer, and liquid-crystal display device |
GB2515603B (en) | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
CN105050594B (en) | 2013-03-19 | 2019-11-12 | 南佛罗里达大学 | For generating the composition and method that increase with lasting ketosis |
WO2014190251A1 (en) | 2013-05-24 | 2014-11-27 | Genomatica, Inc. | Microorganisms and methods for producing (3r)-hydroxybutyl (3r)-hydroxybutyrate |
US9790195B2 (en) * | 2013-08-06 | 2017-10-17 | Imago Biosciences, Inc. | KDM1A inhibitors for the treatment of disease |
US20180008629A1 (en) | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
WO2017011294A1 (en) | 2015-07-10 | 2017-01-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
RU2761829C2 (en) | 2016-06-07 | 2021-12-13 | Зе Дж. Дэвид Глэдстоун Инститьютс | Esters of beta-hydroxybutyrate and butanediol formed by medium-chain fatty acids and compositions and methods based on them |
BR112020001285A2 (en) | 2017-07-21 | 2020-07-28 | Buck Institute For Research On Aging | beta-hydroxybutyrate and butanediol s-enantiomers and methods for their use |
US20210094900A1 (en) | 2018-01-25 | 2021-04-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
US20190262415A1 (en) | 2018-02-26 | 2019-08-29 | Ketologie LLC | Supplement for inducing and sustaining nutritional ketosis |
-
2017
- 2017-06-02 RU RU2018143895A patent/RU2761829C2/en active
- 2017-06-02 CN CN201780041428.2A patent/CN109477993B/en active Active
- 2017-06-02 KR KR1020197000530A patent/KR102519244B1/en active IP Right Grant
- 2017-06-02 CA CA3026621A patent/CA3026621A1/en active Pending
- 2017-06-02 US US16/306,524 patent/US10889538B2/en active Active
- 2017-06-02 EP EP17810768.6A patent/EP3465335A4/en active Pending
- 2017-06-02 AU AU2017278099A patent/AU2017278099B2/en active Active
- 2017-06-02 MX MX2021009806A patent/MX2021009806A/en unknown
- 2017-06-02 KR KR1020227044586A patent/KR102638807B1/en active IP Right Grant
- 2017-06-02 WO PCT/US2017/035826 patent/WO2017213999A1/en active Application Filing
- 2017-06-02 CN CN202111675586.8A patent/CN114292190A/en active Pending
- 2017-06-02 JP JP2018564979A patent/JP7058610B2/en active Active
- 2017-06-02 MX MX2018015302A patent/MX2018015302A/en unknown
- 2017-06-02 SG SG11201810765PA patent/SG11201810765PA/en unknown
-
2018
- 2018-12-06 IL IL263561A patent/IL263561B/en unknown
- 2018-12-26 CO CONC2018/0014167A patent/CO2018014167A2/en unknown
-
2019
- 2019-07-29 US US16/525,437 patent/US10562839B2/en active Active
- 2019-07-31 US US16/528,524 patent/US10647658B2/en active Active
-
2020
- 2020-12-02 US US17/110,236 patent/US11608308B2/en active Active
-
2021
- 2021-06-07 AU AU2021203726A patent/AU2021203726C1/en active Active
- 2021-10-26 JP JP2021174538A patent/JP7479337B2/en active Active
-
2022
- 2022-03-24 IL IL291694A patent/IL291694A/en unknown
-
2023
- 2023-12-21 JP JP2023215845A patent/JP2024028287A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201808337TA (en) | Deactivation wipe kit and method of forming and using the same | |
SG11201811237WA (en) | Combination therapies | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804721SA (en) | Modulators of complement activity | |
SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
SG11201408171SA (en) | Fbxo3 inhibitors | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201901070YA (en) | Formulations for oral administration of active agents | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |